Bristol reviews Plavix ad
Executive Summary
Bristol-Myers Squibb has conducted an audit of a recent Plavix direct-to-consumer ad and maintains that there is no difference in the speed of delivery between efficacy and safety/risk information in voiceovers. At a recent Regulatory Affairs Professional Society DTC conference, a Bristol regulatory director agreed with attendees that the voice delivering the safety information was faster (1"The Pink Sheet" May 22, 2006, p. 27). Attendees also said the change from a male voice to a female voice for delivery of the safety/risk information was distracting. Bristol said it intentionally switched voices to call attention to safety/risk information and noted that the ad was pre-cleared by FDA...
You may also be interested in...
DTC Guideline Implementation: Does “Ask Your Doctor” Spark A Dialogue?
As industry continues to implement PhRMA's guidelines on direct-to-consumer ads, debate has arisen as to how companies can effectively enact the principle that advertising should encourage a conversation between patient and physician
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.